Abstract
ABSTRACT
Gout is a common inflammatory disease closely associated with hyperuricemia, and its global prevalence is increasing, highlighting the need for safer and more effective therapeutic strategies. Recently, microbiome‐based therapeutics have emerged as promising alternatives, and the development of functionally validated NGP and their advanced forms, post–NGP strains, is gaining increasing attention. In this study, microbiome‐derived bacterial strains were screened based on their in vitro uric acid (UA)‐reducing capacity and hypoxanthine utilization. Among the tested strains,
Mitsuokella jalaludinii
exhibited the most pronounced uric acid reduction and growth enhancement in response to purine substrates compared to conventional lactic acid bacteria. This strain reduced uric acid levels by approximately 30% after 48 h (
p
p
p
d
‐lactate production, cytotoxicity assays and oral toxicity assessment in a mouse model, demonstrated that PMC73 exhibited no pathogenic or toxic properties. Therefore, PMC73 represents a promising microbiome‐based candidate with relevance to gout‐associated hyperuricemia, warranting further in vivo and clinical investigations.